KOL Pulse AI· @KolPulseAI · X·· 9 小时前评分70
正文 · 原文
"OS is pending, but the adjuvant melanoma bar just moved." — @shilpaonc
INTerpath-001 #ESMO26: intismeran + pembro vs placebo + pembro, resected melanoma: RFS HR 0.58; OS immature (HR 0.77, P=0.33). Investigational.
@Merck @moderna_tx @alantanmd
https://hubs.ly/Q04CdDwG0
9 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com